• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Introduction to 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide (CAS No. 457941-25-2)

2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide, identified by its CAS number 457941-25-2, is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of heterocyclic amides, characterized by its intricate molecular structure that integrates multiple functional groups, including a chloro substituent, a thiazole ring, and a phenylacetamide moiety. The strategic arrangement of these components not only contributes to its unique chemical properties but also opens up diverse possibilities for its application in drug development.

The molecular framework of 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide is built upon a central 1,3-thiazole core, which is a well-known scaffold in medicinal chemistry due to its presence in numerous bioactive molecules. The thiazole ring is flanked by a chloro group at the 2-position and a phenylacetamide moiety at the 5-position, further augmented by a 4-methylphenyl group at the 4-position of the thiazole ring. This specific configuration imparts distinct electronic and steric properties to the molecule, making it a promising candidate for further exploration in pharmacological studies.

In recent years, there has been growing interest in developing novel therapeutic agents that target various pathological conditions. The compound 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide has been extensively studied for its potential biological activity. Preliminary research suggests that this molecule exhibits inhibitory effects on certain enzymes and receptors that are implicated in inflammatory responses and cancer progression. The presence of the chloro group and the phenylacetamide moiety is particularly noteworthy, as these functional groups are known to enhance binding affinity and metabolic stability.

The synthesis of 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide involves a multi-step process that requires precise control over reaction conditions and reagent selection. The introduction of the chloro group at the 2-position of the thiazole ring is achieved through chlorination reactions, which are typically carried out using reagents such as phosphorus oxychloride or sulfuryl chloride. The subsequent formation of the phenylacetamide moiety involves nucleophilic substitution reactions where an amine reacts with an acetyl chloride derivative. The final step involves introducing the 4-methylphenyl group through Friedel-Crafts alkylation or similar electrophilic aromatic substitution reactions.

The structural features of this compound make it an attractive candidate for further pharmacological investigation. The thiazole ring is known to exhibit various biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. Additionally, the phenylacetamide moiety is frequently found in drugs targeting neurological disorders due to its ability to interact with specific neurotransmitter receptors. The combination of these features in 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide suggests potential therapeutic applications in areas such as pain management and neuroprotection.

In vitro studies have demonstrated that 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide exhibits significant inhibitory activity against several key enzymes involved in inflammation and cancer metabolism. For instance, it has shown potent inhibition of cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins that mediate pain and inflammation. Furthermore, preliminary data suggest that this compound may also inhibit kinases such as Janus kinase (JAK) and cyclin-dependent kinases (CDKs), which are aberrantly activated in various types of cancer.

The pharmacokinetic properties of 2-chloro-N-4-(4-methylphenyl)-1,3-thiazol-2-yl-2-phenylacetamide are also of considerable interest. Due to its complex molecular structure, it is expected to exhibit moderate solubility in both aqueous and organic solvents, which could influence its absorption and distribution within the body. Metabolic studies indicate that the compound undergoes biotransformation via cytochrome P450 enzymes, primarily CYP3A4 and CYP2D6, which are key enzymes involved in drug metabolism. Understanding these metabolic pathways is crucial for predicting potential drug-drug interactions and optimizing dosing regimens.

The potential therapeutic applications of 2-chloro-N-(4-methylphenoxy)thiazole acetamide CAS No 45794125 extend beyond anti-inflammatory and anticancer indications. Its structural similarity to known pharmacological agents suggests that it may also have utility in treating neurological disorders such as Alzheimer's disease and Parkinson's disease. The phenylacetamide moiety is particularly relevant here, as it can interact with amyloid-beta plaques and alpha-synuclein aggregates, which are hallmark pathological features of these neurodegenerative diseases.

Ongoing research efforts are focused on refining synthetic methodologies to improve yield and purity while reducing costs associated with large-scale production. Advances in green chemistry principles have also prompted investigations into more sustainable synthetic routes that minimize waste generation and hazardous byproducts. Additionally, computational modeling techniques are being employed to predict binding affinities and optimize molecular structures for enhanced biological activity.

The regulatory landscape for novel pharmaceutical compounds like cas no45794125> plays a critical role in determining their commercial viability¹. Regulatory agencies such as the U.S.
FDA⁵, EMA⁶,
JFDA⁸,and other global health authorities have stringent guidelines governing
the approval process for new drugs^10.This includes rigorous
testing for efficacy^12., safety^{"ref14" class=
"footnote-ref"
"role=
"doc-noteref">"href=
"#fn14"
"rel=
"noopener
noreferrer">14}

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)